Survival from early, intermediate, and late stages of HIV infection

被引:104
作者
Enger, C
Graham, N
Peng, Y
Chmiel, JS
Kingsley, LA
Detels, R
Munoz, A
机构
[1] JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205
[2] JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205
[3] NORTHWESTERN UNIV,SCH MED,DEPT PREVENT MED,CHICAGO,IL
[4] UNIV PITTSBURGH,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15260
[5] UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024
[6] UNIV CALIF LOS ANGELES,GRAD SCH PUBL HLTH,LOS ANGELES,CA 90024
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1996年 / 275卷 / 17期
关键词
D O I
10.1001/jama.275.17.1329
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To estimate expected survival time among homosexual men infected with the human immunodeficiency virus type 1 (HIV-1) by (1) the calendar period before (1985-1988) and after (1989-1993) the widespread availability of acquired immunodeficiency syndrome (AIDS) treatments with antiretroviral and prophylactic interventions, acid (2) stage of HIV disease. Design.-A prospective cohort study. A group of HIV-1-infected homosexual men were followed from July 1985 through June 1993 and evaluated every 6 months for the presence of clinical symptoms and measurement of the CD4 cell count, To measure the effectiveness of AIDS therapies in this nonrandomized study, we used 2 calendar periods as proxy measures of relative intensity of exposure to antiretroviral therapy. Stage of infection was defined by CD4 cell count and presence of HIV-related clinical symptoms or AIDS. Setting and Study Participants.-Homosexual men infected with HIV-1 from the Multicenter AIDS Cohort Study. Main Outcome Measure.-Survival time based on stage of HIV infection. Results.-The percentage of HIV-1-infected individuals free of AIDS and clinical symptoms at baseline who survived 2.5 years according to baseline CD4 cell counts of 0 to 0.100, 0.101 to 0.200, and 0.201 to 0.350 x 10(9)/L was 22%, 53%, and 83%, respectively, for the 1985-1988 calendar period, compared with 54%, 71%, and 91%, respectively, for men in the 1989-1993 calendar period. Among men free of AIDS with CD4 cell counts of greater than 0.350 x 10(9)/L, the relative hazard of mortality was 1.6 to 2.3 times higher for those with clinical symptoms compared with those free of clinical symptoms. Conclusions.-Survival of AIDS-free HIV-1-infected individuals with CD4 cell counts of less than 0.350 x 10(9)/L has improved since antiretroviral and HIV prophylactic treatments have become available, but the long-term prognosis remains poor.
引用
收藏
页码:1329 / 1334
页数:6
相关论文
共 37 条
[1]   INCUBATION PERIOD OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].
ALCABES, P ;
MUNOZ, A ;
VLAHOV, D ;
FRIEDLAND, GH .
EPIDEMIOLOGIC REVIEWS, 1993, 15 (02) :303-318
[2]   SURVIVAL PATTERNS OF THE 1ST 500 PATIENTS WITH AIDS IN SAN-FRANCISCO [J].
BACCHETTI, P ;
OSMOND, D ;
CHAISSON, RE ;
DRITZ, S ;
RUTHERFORD, GW ;
SWIG, L ;
MOSS, AR .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (05) :1044-1047
[3]  
BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737
[4]   ZIDOVUDINE IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION AND CD4+ CELL COUNTS GREATER-THAN 400 PER CUBIC MILLIMETER [J].
COOPER, DA ;
GATELL, JM ;
KROON, S ;
CLUMECK, N ;
MILLARD, J ;
GOEBEL, FD ;
BRUUN, JN ;
STINGL, G ;
MELVILLE, RL ;
GONZALEZLAHOZ, J ;
STEVENS, JW ;
FIDDIAN, AP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :297-303
[5]  
Cox D. R., 1984, ANAL SURVIVAL DATA
[6]   THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
HANSEN, N ;
COLLIER, AC ;
CAREY, JT ;
PARA, MF ;
HARDY, WD ;
DOLIN, R ;
POWDERLY, WG ;
ALLAN, JD ;
WONG, B ;
MERIGAN, TC ;
MCAULIFFE, VJ ;
HYSLOP, NE ;
RHAME, FS ;
BALFOUR, HH ;
SPECTOR, SA ;
VOLBERDING, P ;
PETTINELLI, C ;
ANDERSON, J .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) :727-737
[7]   THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
SCHOOLEY, RT ;
JACKSON, GG ;
DURACK, DT ;
KING, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191
[8]  
GAIL MH, 1995, AIDS CLIN TRIALS, P403
[9]   QUALITY-CONTROL IN THE FLOW CYTOMETRIC MEASUREMENT OF LYMPHOCYTE-T SUBSETS - THE MULTICENTER AIDS COHORT STUDY EXPERIENCE [J].
GIORGI, JV ;
CHENG, HL ;
MARGOLICK, JB ;
BAUER, KD ;
FERBAS, J ;
WAXDAL, M ;
SCHMID, I ;
HULTIN, LE ;
JACKSON, AL ;
PARK, L ;
TAYLOR, JMG .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 55 (02) :173-186
[10]   THE EFFECTS ON SURVIVAL OF EARLY TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
GRAHAM, NMH ;
ZEGER, SL ;
PARK, LP ;
VERMUND, SH ;
DETELS, R ;
RINALDO, CR ;
PHAIR, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (16) :1037-1042